SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-025325
Filing Date
2021-05-07
Accepted
2021-05-07 08:31:03
Documents
69
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ljpc-10q_20210331.htm   iXBRL 10-Q 1411680
2 EX-31.1 ljpc-ex311_9.htm EX-31.1 18323
3 EX-31.2 ljpc-ex312_6.htm EX-31.2 18389
4 EX-32.1 ljpc-ex321_8.htm EX-32.1 15869
5 GRAPHIC gc2kqtjgsywv000001.jpg GRAPHIC 67979
  Complete submission text file 0001564590-21-025325.txt   6253132

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20210331.xsd EX-101.SCH 56720
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ljpc-20210331_cal.xml EX-101.CAL 63229
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ljpc-20210331_def.xml EX-101.DEF 185256
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20210331_lab.xml EX-101.LAB 419432
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20210331_pre.xml EX-101.PRE 312366
11 EXTRACTED XBRL INSTANCE DOCUMENT ljpc-10q_20210331_htm.xml XML 952663
Mailing Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE, SUITE 240 SAN DIEGO CA 92121 858-207-4264
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36282 | Film No.: 21900381
SIC: 2836 Biological Products, (No Diagnostic Substances)